⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LTRN News
Lantern Pharma Inc. Common Stock
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
businesswire.com
LTRN
RedChip's Biotech Investor Conference Replays Now Available
accessnewswire.com
SXTP
BIVI
BFRG
LTRN
NXL
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
businesswire.com
LTRN
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
businesswire.com
LTRN
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST)
accessnewswire.com
MDCX
SDST
VTIX
VVOS
YYGH
DVLT
CISO
LTRN
CAST
Form 8-K
sec.gov
LTRN
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference
accessnewswire.com
SXTP
BIVI
BFRG
LTRN
NXL
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
businesswire.com
LTRN
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
businesswire.com
LTRN
Form 8-K
sec.gov
LTRN